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Factor V Leiden, is a variant of human factor V (FV), also known as proaccelerin, which leads to a hypercoagulable state. Along
these years, factor V Leiden (FVL) has been studied from the pathophysiologic point of view, and research has been focused on
ﬁnding clinical approaches for the management of the FVL associated to a trombophilic state. Less attention has been paid about
thepossibleroleofFVLininﬂammatoryconditionsknowntobepresentindiﬀerentdisorderssuchasuremia,cirrhosis,livertrans-
plantation,depressionaswellassepsis,infectionor,inﬂammatoryboweldisease(IBD).WhetherplateletFVLwillincreasetheacti-
vationofcoagulationand/orinwhichproportionisabletodeterminetheﬁnaloutcomeinthepreviouslymentionedinﬂammatory
conditions is a subject that remains uncertain. This paper will review the association of FVL with inﬂammation. Speciﬁcally, it will
analyze the important role of the endothelium and the contribution of other inﬂammatory components involved at both the im-
mune and vascular levels. This paper will also try to emphasize the importance of being a FVL carrier in associations to diseases
where a chronic inﬂammation occurs, and how this condition may be determinant in the progression and outcome of a speciﬁc
clinic situation.
1.Introduction
Coagulation factor V (FV), also known as proaccelerin or
labile factor, is synthesized in the liver and circulates as a
single chain polypeptide in an inactive procoagulant form
[1]. Although most FV is present in plasma, approximately
20% of the circulating FV is found within α-granules [2].
Platelet FV is partially proteolysed and is stored bound to
the protein multimerin inside those granules [3]. Factor V
plays a key role as a cofactor of the prothrombinase com-
plex that cleaves and activates prothrombin to thrombin
leading the formation of the blood clot [4]. Factor V Leiden
(FVL) is the name of a speciﬁc gene mutation which leads to
a hypercoagulability state with serious clinical consequences
[5]. Less than two decades of its discovery, the pathophysiol-
ogy, clinical consequences, and therapeutic management of
the thrombophilic state associated to this condition remains
object of controversies [6]. The excessive clotting that occurs
inthisFVdisorderismostlyrestrictedtothevenousterritory
and it’s known to be the most frequent contributors to cause
deep vein thrombosis (DVT) [7, 8].
Sometimesvenousclotsmaybreakoﬀandtravelthrough
the heart and lung blocking vessels causing pulmonary em-
bolisms. On the other hand, although seems less common
the formation of clots in arteries, they may lead to stroke
or myocardial infarction (ministroke or transient ischemic
attacks) [9]. Interestingly, in the last years, major attention
is being paid on how venous thromboembolism (VTE) is
becoming a serious public health problem contributing to
a steadily increasing mortality in our modern societies [10,
11].
It is well known that venous thrombosis (VT) occurs as
a result of a combination of genetic and environmental risk
factors such as age, surgery, trauma, cancer, pregnancy, and
use of hormonal therapy. The presence and interaction of
one or more of those risk factors will determine the relative
riskofdevelopingVT.FVLmutationwillfurtherenhancethe
riskofdevelopingabnormalclots,beingcurrentlyconsidered
the most common cause of Thrombophilia [10].
A more limited information is available on the impact of
FVL in clinical events where inﬂammation is prevalent [12,
13]. Uremia, cirrhosis, liver transplantation, but also sepsis2 Thrombosis
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Figure 1: Coagulation cascade.
(generalized inﬂammatory state also known as SIR-systemic
inﬂammatory response), infection, and Inﬂammatory Bowel
Disease (IBD) result in a chronic inﬂammatory state. Even
though,bothmechanismsofactionandclinicalmanagement
of the previous conditions are well established, it has not
been possible to reach a ﬁnal consensus on whether FVL is
able to modify the outcome of these events.
The inﬂammatory response is a complex reaction which
impliestheinteractionofvasculartissues,coagulationmech-
anisms, and blood cell components, mainly platelets (Plts)
and leukocytes [14, 15]. Platelets are the main blood “cell”
element involved in the formation of the clot [16]. Attach-
ment to the subendothelium, activation with release of its
granule content, and aggregation provide the appropriate
environment for the activation of the coagulation mecha-
nisms [17, 18]. During this process, FV, released upon plate-
let activation, plays a crucial role in the early phase of the
coagulation expressed in its an active form (FVa) for imme-
diate and sustained procoagulant function at sites of vessel
injury. Leukocytes and cytokines they produce, are critically
involved in initiating and maintaining the inﬂammatory
response. These cells will be recruited and attracted at the
site of injury through selectins which became exposed on
inﬂammated endothelium or on activated platelets.
In past years, researchers have been mainly focused on
the insights of the immune and coagulation systems during
the inﬂammatory response, but less attention has been paid
to the role of the damaged endothelium, activated Plts, and
circulating microparticles (MPs) potentiating the abnormal
functionalityofFVL.Availableliteratureonthepossiblerela-
tion among FV mutations, platelet function, and increased
number of circulating MPs is relatively scarce [19].
Through the following text, we will review the associ-
ation of FVL with inﬂammation as well as provide new
insights/other aspects, which may contribute to a better
understanding of speciﬁc diseases, which undergo chronic
inﬂammationincludingsepsis,infection,and/orIBD.Special
attentionwillbepaidtothecontributionoftheendothelium,
activatedplateletsandderivedMPsascarriersnotonlyofFV,
but of Tissue Factor (TF) during inﬂammatory conditions
and its possible implications in thrombotic complications in
patients diagnosed with FVL.
2.Pathophysiology ofFactorV:
Factor V Leiden Mutation
Blood clots form in two steps. In the ﬁrst step, activated Plts
release the content of stored granules into the blood plasma
(primary Hemostasis) and aggregate forming an initial plug
or clot. In a second step, Plts attract more Plts and coagu-
lation factors become activated [20]. Overall, Plts are associ-
atedtogetherwiththecoagulationproteinsandcontributeto
ﬁbrin generation that will stabilize the blood clot [17].
FactorV protein circulatesin thebloodstream asaninac-
tive form until the coagulation system is activated due to
a damage in blood vessels. In a normal state, activated FV
(FVa) acts as a cofactor that interacts with active Factor X
to convert the inactive enzyme prothrombin into throm-
bin which cleaves Fibrinogen to Fibrin [4]. Then, Fibrin
polymerizes leading to the formation of the blood clot
(see Figure 1). Participation of activated protein C (APC)
as a natural anticoagulant limits the extent of clotting by
cleaving and degrading FV [21]. Activated protein C (APC)
cleaves FV at speciﬁc sites (at protein position 506) and
downregulates its function therefore preventing the excessive
growth of the clot [3, 22]. Cleavage of FV will also allow
this coagulation factor to inactivate factor VIIIa, another
essential protein for the normal blood clotting process [23–
25]. APC is unable to inactivate FV when the mutationThrombosis 3
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on this coagulation protein occurs: single change of one
aminoacid at position 506; an arginine (Arg) is replaced by
a glutamine (Gln) (see Figure 2)[ 26]. As a result of this, the
mutation leads to a loss of anticoagulant cofactor function
of APC on FV with clotting mechanisms remaining active
for more prolonged periods and a subsequent increase of
the formation of pathological blood clots. This is the reason
why FVL disorder was initially described as APC resistance,
although the FVL mutation is only found in about 80–90%
of cases diagnosed with this condition [6, 27, 28].
The FVL mutation is currently the most common known
risk factor for VT. Factor V Leiden is an autosomal dominant
condition only present in Caucasians, and the prevalence
v a r i e sb e t w e e n2 %t o1 5 %[ 29]. It has been demonstrated
that the mutation is less common in other populations such
as Hispanics and African-Americans, and it’s extremely rare
in people of Asian descent [30, 31]. The polymorphism
occurred from a common source about 30000 years ago
(founder eﬀect) and between 3–8% of people with European
ancestry and 5% of Caucasians in North America carry one
copy of FVL mutation, meanwhile about 1% (5,000 people
approximately) has two copies of the mutation [32].
The presence of the FVL mutation considerably increases
the risk of developing abnormal blood clotting. The most
common clinical manifestations of FVL are superﬁcial and
DVT. Actually, up to 30% of patients who presents DVT has
been diagnosed with this condition [10]. The risk of devel-
oping thrombotic episodes depends on whether a person has
one or two copies of the FVL mutation. Inheritance of two
copies of the mutation, one from each parent, signiﬁcantly
increases the risk of developing thrombotic complications
[33]. Overall, those who are homozygous for the mutated
allele present an increasing risk of developing abnormal clots
(50–100 fold) versus those that are heterozygous for the
mutation(5–10fold)whoactuallypresentaquitelowriskfor
venous thrombosis [31]. It is important to consider that the
combined association of another acquired risk factors for
VT such as age, obesity, smoking, use of birth control pills
(estrogen based hormonal contraception), or hormone rep-
lacementtherapyrecentsurgery,willfurtherenhancetherisk
for an individual carrying with the FVL mutation to develop
DVT [34].Furthermore,theassociationoftheFVLmutation
with another mutation in another gene involved in the
coagulation system will cause an extremely high risk of deve-
loping abnormal clots. In this context, coexistence of het-
erozygous FVL mutation and the G20210A mutation in the
prothrombin gene is the most frequent abnormality causing
VTE [35, 36]. Moreover, combinations of FVL, antithrom-
bin, protein C or protein S deﬁciencies and hyperhomo-
cystienemia, have been found to result in a 5-to-10 fold in-
crease in the relative risk of thrombosis (see Table 1-adapted
from “Natural anticoagulants and thrombophilia”) [37, 38].
AlthoughFVsynthesiswaspreviouslydeterminedtotake
place in megakaryocytes [39], Christiella et al. [25]w e r ea b l e
to demonstrate that plasma is the principal origin for platelet
FV. However, a small proportion of FV is found within the
platelet α-granules. Gould et al. [3] provided a strong evi-
dence that once FV stored in α-granules is a diﬀerent sub-
strate. Once being endocytosed by megakaryocyte and deliv-
ered to Plts, FV is cleaved to a partially active cofactor,
which appears to be more resistant to APC inactivation. This
ﬁnding supported the research of Camire et al. [40]d e m o n -
stratingthatcompleteinactivationofplatelet-derivedFVwas
never accomplished. According to the previous studies, FVa
thatexpressedonactivatedPltscouldbeprotectedfrominac-
tivationbyAPC.Furtherexperimentsalsodemonstratedthat4 Thrombosis
Table 1:Geneticrisksfactorinvenousthromboembolism(adapted
from [38]).
Genetic risk Deﬃciency or
alteration
Frequency in patients
with thrombosis
Strong genetic risk Antithrombin 2–5%
Protein C 2–5%
Protein S 2–5%
Moderate genetic risk Factor V Leiden 18–35%
Prothrombin
G20210A 7–10%
Homocystinemia 18–20%
Dysﬁbrinogehemia 10%
Variable genetic risk Elevated levels FI.
FVIII, FIX, FXI 15–30%
Acquired condition Antiphospholipid
antibody/syndrome 5–10%
Pregnancy —
Cancer —
the platelet-derived MPs resulted in increased levels/rates of
thecofactorinactivationsuppressingtheapparentprotection
developed by intact Plts [41]. This is an important point to
take into consideration since elevated levels of circulating
MPshavebeenreportedinpatientsdiagnosedwithFVL[19].
Further studies have demonstrated that levels of MPs may
correlate with plasma levels of FVL thus suggesting that the
ratio FVL/FV ratio could be a parameter to predict the risk
of thrombosis in carriers of FVL [42].
3.Pathophysiology of Inﬂammation:Role of
EndothelialDysfunction,Platelets,andMPs
Inﬂammation can be deﬁned as a complex biological res-
ponse of protection to a wide variety of harmful stimulus.
This inﬂammatory response undergoes with a break of the
balance of the coagulation and alterations at multiple levels
involving damage at vascular tissues, reaction of leukocytes
releasing interleukins and cytokines, and activation of plate-
lets [15, 43]. Inﬂammation is classiﬁed as acute or chronic.
Acuteinﬂammationistheinitialresponseofthebodyleading
to a cascade of biochemical events based on the interaction
of the vascular and immune system. Persistent or chronic in-
ﬂammation results in elevation of several procoagulant pro-
teins such as ﬁbrinogen and Factor VIII that have been
considered as contributors to the development of a throm-
bophilic state [38]. Chronic inﬂammatory response may lead
toadisruptionoftheprocoagulant/anticoagulanthemostatic
equilibriumtogetherwithotheralterationsatmultiplelevels.
Brieﬂy, there is a reaction of blood cells, mainly leukocytes,
which release interleukins and cytokines that will perpetuate
the inﬂammatory response [43, 44].
Endothelial dysfunction is almost a constant in the in-
ﬂammatoryprocess[45].Asaresultoftheinﬂammatoryres-
ponse, the permeability of the blood vessels increase and rec-
ruitment of leukocytes at the site of injury is initiated. Basi-
cally, endothelial disruption causes the increased expression
of new adhesion molecules such as E-selectin, PECAM-
1 (platelet-endothelial cell adhesion molecule 1), VCAM-1
(vascular cell adhesion protein 1), ICAM-1 (Inter-cellular
adhesion molecule 1), endothelin-1, release of Von Wille-
brand factor (vWF), and P-selectin and L-selectin from stor-
age granules known as Weibel-Palade bodies [46, 47]. Endo-
thelial-selectin expressions are essential for leukocyte rolling
and inﬁltration into the vessel wall [48]. Moreover, exposure
of TF on the endothelial surface, which is upregulated by
multiple inﬂammatory proteins, activates the coagulation
cascade and promotes the procoagulant activity of Plts [49–
51]. All these changes facilitate the adhesion and activation
of Plts to the damaged endothelium establishing a favorable
environment for thrombus formation [18, 52, 53]. Alter-
ations caused by the endothelial dysfunction are aggravated
by the fact that during prolonged inﬂammation, both mech-
anisms of nitric oxide and prostacyclin production are also
impaired promoting the adhesion of the Plts to endothelium
[45].
Formation of MPs has also revealed an important event
fortheinﬂammatoryprogression[54,55].Microparticlesare
small portions of membrane shed from activated cells such
as endothelial, monocytes, and/or platelets which support
procoagulant activity and contribute to the formation of the
hemostatic plug [41, 56–58]. In 2004, Lopez et al. [45, 59]
proposed a model based on monocytes/macrophages deri-
ved microvesicles (MVs) bearing TF with the ability to fuse
withactivatedendothelialcellsduetoinﬂammationandpro-
mote the initiation of blood coagulation. Therefore, endo-
thelial-derived adhesion molecules, speciﬁcally P- and E-
selectin would play a key role interacting with platelets and
circulating MVs/MPs bearing TF. Transfer of TF to the endo-
thelial cells will promote the procoagulant activity, enhanc-
ing the thrombin generation and the formation of the clot
[60–62]. The contribution of circulating MPs to inﬂamma-
tionwasshownagainwhenSalanovaetal.[63]demonstrated
that platelet GPIIb-IIIa receptor is acquired by neutrophils
viaPlt-derivedMPsleadingtheactivationofNF-κβ signaling
cascade supporting the inﬂammatory response [64].
A recent publication has reviewed the important role of
Plts and Plts-derived MPs not only in hemostasis and coag-
ulation but in some other diseases including: atherosclerosis
and related diseases, pathologies of the central nervous sys-
tem (Alzheimer’s disease, Multiple Sclerosis), and even can-
cer and/or Tumour growth [65]. Thus, Plts are essential for
the innate immune response, combat infections (viruses,
bacteria, and microorganisms) and develop an important
role during the inﬂammatory processes [66].
4. FactorVLeidenandInﬂammation:Infection,
Sepsis,andInﬂammatory BowelDisease
During all these years, research in FVL polymorphisms has
been centered on determining the risk of possible throm-
botic complications in diﬀerent clinical situations (surgery,
pregnancy) and evaluating the risk/beneﬁt of prophylactic
treatments. Less attention has been paid to the possible
association of FVL with inﬂammation [67]. Within past 5Thrombosis 5
years,someresearchershavestartedtoquestionwhetherFVL
may be a key condition determining the outcome of clinical
episodes such as infection, sepsis and/or IBD [68]. Less has
been discussed about the possible eﬀect of the Plts and
platelet-derived MPs as a carriers of a modiﬁed FVL and in
which level they may be able to modulate the outcome of this
process associated to sepsis, infection, or/and IBD [42].
4.1. Infection and Sepsis. Infection and severe sepsis imply an
inﬂammatory process with an important alteration in their
coagulation system [49, 69]. In the majority of cases, sepsis
is usually caused by the presence of a known or suspected
infection. In septic patients, all three of the classic Virshow’s
triad are present and culminate in compromised blood ﬂow
tovitalorganscausingamajororganfailure.Thecoagulation
abnormalities in septic patients are profound and life threat-
ening [70]. In 2004, Weiler et al. [71]t r i e dt od e m o n s t r a t e
thatthepolymorphisminFVLwasabletomodifysepsisout-
come according to animal models. However, further studies
could not ﬁnd a signiﬁcant correlation between FVL and
someotherhemostaticpolymorphismsaspredictorsofprog-
nosis of sepsis [72–74].
In 2008, Lindqvist and Dahlb¨ ack [75] indicated the pos-
sibility of FVL being an evolutionary advantage against spe-
ciﬁc events such as sepsis based on the high prevalence in
the general population. In the same line, Isma et al. [76]
also supported that thrombotic events may be considered
a survival advantage against speciﬁc physiological condi-
tions, speciﬁcally in women. In contrast to this idea, numer-
ous publications revealed that the risk of suﬀering miscar-
riage during pregnancy in women carrying FVL is slightly
increased (two or three upfold) as well as presenting compli-
cations derived of clotting episodes during pregnancy such
as suﬀering DVT, pulmonary embolism, preeclampsia, slow
fetal growth, and/or early separation of the placenta from
the uterine wall (placental abruption) [77, 78]. Concentrates
of APC have been considered to have a beneﬁcial eﬀect
when associated to the standard therapy (antibiotics, ﬂuids,
and blood components) for sepsis. Besides its anti-thrombin
eﬀect, APC holds anti-inﬂammatory action due to its inter-
action with white blood cells and endothelial cells [79–81].
Since Plts and MPs are carriers of a FVL modiﬁed which
becomes resistant to the inactivation of APC, it would be
interesting to evaluate to which extent the APC treatment is
equally eﬀective in carriers of FVL or even if it will be able
to inﬂuence an earlier or delayed response to the standard
treatment.
As in sepsis, publications are also controversial about the
inﬂuence of FVL mutation in the outcome of infections such
as pneumonia or ﬂu [70]. Meanwhile, Schouten et al. [82]
were able to ﬁnd some diﬀerences in the outcome of pneu-
mococcal pneumonia, further studies revealed that no signi-
ﬁcant changes were found in the outcome of infection by
lethal H1N1 inﬂuenza.
Various publications have revealed that abundant circu-
latingMPsarepresentduringacuteinfectionssuchasinplas-
modium vivax infection. This ﬁnding supports the idea that
not only Plts but also platelet derived-MPs may play a role
on the acute inﬂammatory symptoms which occur during
infections [83].
4.2. Inﬂammatory Bowel Disease. Inﬂammatory bowel dis-
ease (IBD) is known as a group of inﬂammatory conditions
of the colon and small intestine and usually, it refers to two
chronic diseases: ulcerative colitis and Crohn’s disease. A
hypercoagulable state has been recognized in patients with
IBD.Infact,patientssuﬀeringfromIBDhaveaboutthreefold
increased risk of VT [84, 85].
Numerous studies have been performed in an attempt to
detect a relationship with the presence of FVL mutation and
the incidence of IBD [86]. The majority of publications have
not found a clear association between FVL and the risk of
developing IBD, although FVL continues to be considered a
risk factor which may inﬂuence the clinical manifestations
during IBD [84, 86–88]. Similarly, Liang et al. [89] revealed
that FVL mutation was not signiﬁcantly associated with the
risk of developing IBD. In contrast with the previous reports,
studies by Magro et al. [90] support the concept of higher
prevalence of single and combined thrombophilic defects in
IBDpatients,statingthatthesefactorsmaybeinvolvedinthe
disease pathogenesis. There is no ﬁnal conclusion about the
possible role of FVL mutation but seems clear that presence
of FVL mutation in patients with IBD increases the risk
of developing thrombotic episodes. The pathophysiology of
IBDisstillunderactiveinvestigation.Theinﬂammatorypro-
cess in IBD is probably associated to an immune reaction of
the body against its own vascular tissue [91]. As a result of
this damage, leukocytes and Plts become activated and trig-
ger a chain reaction causing the complete coagulation cas-
cadedysregulationpromotingtheformationofclots[92,93].
Interestingly, elevated levels of circulating MPs have been
found in patients with active IBD. More speciﬁcally, Andoh
et al. [94] were able to determine the increased reaction of
Plts in patients suﬀering IBD having an important role in
its pathogenesis. Immune system reaction against the own
vasculature may generate increased circulating levels of MPs,
which may play a role in enhancing coagulation and inﬂam-
matory states in these patients. Leonetti et al. [95]d e m o n -
strated, using an experimental model, that platelet-derived
MPs inﬂuence and improve both endothelial dysfunction
and vascular hyporeactivity promoting the thrombophilic
state,whichwillbeprobablyenhancedinthosepatientsdiag-
nosed with FVL [54, 96].
5. Final Considerations
Thrombophilic state arises from the interaction of a number
of diﬀerent factors including hereditary deﬁciencies such as
FVL,acquireddeﬁcienciesinnaturalanticoagulantsanddys-
functional coagulation factors with a precipitating clinical
situation [97]. Despite of being considered clinically dif-
ferent, an inﬂammation response is a common early phe-
nomenon, which occurs in numerous clinical situations
including those mentioned before. Following the initial
response, inﬂammation becomes chronic in the majority of
cases reviewed herein causing the worsening of alterations6 Thrombosis
aﬀecting the vessel wall, the immune, and coagulation sys-
tem.
Endothelialdysfunction,initiallydescribedinuremicpa-
tients, has been also reported in a variety of clinical con-
ditions such as cirrhosis, diabetes, liver transplantation,
and even major depression [98, 99]. Inﬂammatory response
occurring during sepsis, infection, and IBD leads to an endo-
thelialdamagecausingavascularresponseandenhancedleu-
kocyte and Plts activation. Release and exposure of adhesion
molecules (e.g., P-selectin, E-selectin, ICAM-1, and VCAM-
1) play a key role in promoting the attachment of leukocytes
and Plts to the subendothelium [18, 100]. The previous
events and the presence of collagen and TF on the damaged
endothelium will trigger the coagulation cascade and the
formation of occlusive thrombi.
Despite the accepted role of the endothelium and Plts
in inﬂammation, less has been discussed on the possible in-
volvement of Plts-and Plt-derived MPs as a carriers of TF
and/or modiﬁed FVL and their implication in the develop-
ment thrombotic complications associated to sepsis, infec-
tion, or/and IBD [101]. Circulating MPs have been found
signiﬁcantly increased in patients diagnosed with FVL [19].
Moreover, elevated circulating MPs have been also detected
in sepsis, infections, and IBD. This fact supports the idea that
Plts and both Plt- and leukocyte-derived MPs may develop
a crucial role in the progression of inﬂammation leading
not only the formation of the clot but also becoming a
predicting factor of the risk of developing thrombosis [42].
It has been demonstrated that MPs increase vascular and
endothelialdysfunction,supportingtheideaofMPscarrying
FVL becoming an enhancerof the prothrombotic events pre-
sented in these patients worsening the clinical management
and outcome.
Previous studies revealed that MPs are heterogeneous
and highlydependent on the activation mechanism thattrig-
gered their production [102]. Furthermore, it has been re-
ported that Plt MPs are carriers of speciﬁc receptors such
as GPIIb-IIIa and other molecules including P-selectin and
more importantly FV [2]. In which proportion FVL is pre-
sent in circulating MPs in FVL disorder as well as during sep-
sis, infection, and/or IBD may open a new strategy for the
clinicalmanagementofthesepatients.Thus,characterization
of MPs in patients diagnosed with FVL as well as in patients
presenting sepsis, infection, and IBD events may provide
valuable information for a better understanding of these dis-
orders and also for the evaluation of the clinical course of
these speciﬁc conditions. In accordance with the later con-
cept, detection of elevated levels of TF-bearing MVs associ-
ated with inﬂammatory conditions would help to explain the
increased risk of thrombosis associated with infections such
as IBD [45].
ThehighernumberofMPsloadedwithproinﬂammatory
components (FV and TF) leads to a procoagulantstate which
may be more intense in patients with FVL developing the
inﬂammatory episodes described in this paper [41]. Taking
into consideration all the ﬁndings reviewed above, it seems
reasonable to consider that patients diagnosed with FVL will
be exposed to enhanced inﬂammatory responses in sepsis,
infection, or IBD not only due to the FVL itself but also
for the high presence of MPs with procoagulant properties.
Moreover,recentﬁndingsshowed thatMPsnot onlyarecon-
sidered vectors of inﬂammation but are also described as the
main responsible of major organ failure in sepsis [103, 104].
PlateletFVhasdemonstratedtobemoreresistanttoAPC
action and seems to be the major responsible to prolong the
thrombin action once the coagulation cascade is activated
[40]. Interestingly, all studies performed trying to elucidate
therelationshipofFVLwiththeoutcomeoftheseeventshave
been focused on the whole pool of FV. Less has been said
about the platelet-derived FV which represents the 20% of
the complete pool. Since platelet-derived FV seems to have a
major resistance to APC inactivation, it may be reasonable to
thinkaboutakeyroleinprolongingthecoagulationresponse
and the fact that this eﬀect may be enhanced when FVL
mutation occurs.
There is considerable debate on whether FVL could be
considered a condition which may lead to an enhanced in-
ﬂammatory response in diﬀerent clinical inﬂammatory con-
ditions. Through the information reviewed herein, it seems
that FVL seems not to determine the incidence of these epi-
sodes, although there is a common consensus on FVL being
considered an important risk factor for the development of
thrombotic events in patients diagnosed with sepsis, infec-
tion,orIBD.Thereisacommonagreementthathomozygous
patientsforFVLwilldevelopthromboticepisodesduringthe
course of such inﬂammatory conditions. It is important to
take into consideration that heterozygousness for the muta-
tion usually present low risk of developing thrombotic com-
plicationsunderphysiologicalconditions.Theriskofthrom-
bosis could increase during an inﬂammatory response. The
presence of the mutation (even in its heterozygous version)
during an inﬂammatory episode may increase the risk of
developing abnormal clots and complicate the normal reso-
lution of the episode or its medical treatment.
6. Conclusion
Patients with FVL present a thrombophilic tendency that
may be enhanced during an inﬂammatory episode occurring
duringsepsis,infection,orIBD.Damageoftheendothelium,
exposure of adhesion molecules, and the participation of
procoagulant components involved in inﬂammation with
activation of leukocytes and Plts as well as increased levels
of Plts-derived MPs carrying TF and FVL play a key role in
upregulating the underlying thrombophilic state even in
patients with the heterozygous FVL mutation.
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DVT: Deep venous thrombosis
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